Furthermore, when patients were stratified by treatment response status, we found that the patients that were response to treatments had better survival than the non-responders in CRC patients harboring high levels of Monocytes/Macrophages S01 and CD8 T cell S01 levels (Fig. 7e, f, p = 0.0011 and 0.0015, log-rank tests). This evidence concerns the gene CD8A and colorectal carcinoma.